Thread by @Raoul__Lucas

We got some more updates on the upcoming trials with #BC007 for #LongCOVID and #MECFS over the last couple of weeks.

In this thread is a short overview of the three planned studies and their current status.

The reCOVer-project at the UK-Erlangen for #LongCOVID, which will be conducted by @Dr_Hohberger and her team, is scheduled to start in the upcoming months.
In recent interviews it was said that the team hopes to be able to start in September/October.

Currently they are still waiting for the delivery of #BC007 from @BerlinCures.

Thirty LongCOVID patients will take part in this trial, ten of them will get a placebo.

The same study will also be made with #MECFS patients.
This trial is now planned to start around spring/summer 2023. According to the @MECfsFundraiser team they will soon announce a concrete date.

https://twitter.com/mecfsfundraiser/status/1555543200890294272?s=21&t=sCQ-OmYZBE_Qwpau4-uDRQ

The third study is the big multinational study by BerlinCures to get an approval for #BC007 for #LongCOVID.

This study is expected to take place at more than 15 centers in Germany, the Netherlands, Switzerland, Spain and Finland.

In March 2022 it was announced by the company that the study would start this summer, but in a recent interview one of the managers confirmed that the trials are now scheduled to start at the end of 2022/early 2023.

Unfortunately BerlinCures has not given a reason for this delay, but it seems like the company is still looking for investors.
The CEO said that many potential investors want to wait until the first results from clinical trials.